{"organizations": [], "uuid": "3eaa33094d7f1af1ae15feb0236f09038138b32e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-psivida-submits-new-drug-applicati/brief-psivida-submits-new-drug-application-for-durasert-three-year-treatment-for-posterior-segment-uveitis-to-the-u-s-fda-idUSASB0C041", "country": "US", "domain_rank": 408, "title": "BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.524, "site_type": "news", "published": "2018-01-08T22:05:00.000+02:00", "replies_count": 0, "uuid": "3eaa33094d7f1af1ae15feb0236f09038138b32e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-psivida-submits-new-drug-applicati/brief-psivida-submits-new-drug-application-for-durasert-three-year-treatment-for-posterior-segment-uveitis-to-the-u-s-fda-idUSASB0C041", "ord_in_thread": 0, "title": "BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "negative"}, {"name": "psivida corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - pSivida Corp:\n* PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA\n* PSIVIDA CORP - ‍SUBMITTED NDA TO U.S. FDA FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T22:05:00.000+02:00", "crawled": "2018-01-09T17:05:58.005+02:00", "highlightTitle": ""}